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The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma Running head: Prognostic value of MRD in relapse myeloma *Bruno PaivaAchieving deep levels of remission is one of the pre-requisites to reach longterm survival in solid tumors and hematological malignancies, and this has also been proved in newly-diagnosed multiple myeloma (MM) patients particularly in the era of novel agents. (1-3) Accordingly, both the Spanish and UK groups have shown the prognostic value and clinical relevance of minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in both newly-diagnosed transplant candidates and elderly MM patients treated with novel agents.(4-6) However, the value of the depth of response in the relapse setting has been far less investigated as compared to the up-front setting. (7) (8) (9) (10) (11) In fact, data exploring different outcomes between patients achieving very good partial response (VGPR) or complete response (CR) with salvage therapy is scanty (7) (8) (9) (10) (11) , and there is no information regarding the prognostic value of achieving immunophenotypic or molecular responses at relapse. If MRD-negativity would translate into superior outcomes similarly to that observed in newly-diagnosed patients, then it could become a desirable end-point for clinical trials exploring new drugs for relapse/refractory patients.
In the present study we focused on a total of 52 patients that after clinical relapse achieved CR with salvage therapy. Patients were divided into two categories: 21 rescued with novel agents followed by allogeneic stem cell transplantation (alloSCT; n=21), and 31 patients rescued and achieving CR with novel agents (in all except six) followed or not by autologous stem cell transplantation (autoSCT) (11 and 14 cases, respectively). First, we focused on the more standard treatment population of the 31 patients attaining CR after salvage therapy in the non-alloSCT setting (Table 1) Afterwards, we focused on the 21 patients in CR after alloSCT, and observed that 10 (48%) failed to eradicate MRD (median of 0.12% clonal PC among total BM leukocytes; range: 0.01% -0.7%). Surprisingly, there were no significant differences according to the presence vs. absence of MRD in TTP (P =.77) among patients in CR after alloSCT.
These observations led us to investigate whether this phenomenon could be associated with a higher incidence of extramedullary relapses (and therefore potentially missed on BM monitoring) after alloSCT. Accordingly, a total of 11 extramedullary relapses were observed among patients in CR after alloSCT, 7 of which among MRD- 
